| Market Cap | 6.82M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -3.45M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 2.00% |
| Sales | 72.1k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -18.00% |
| Dividend | N/A | Price/Book | 0.72 | EPS next 5Y | - | 52W High Chg | -82.00% |
| Recommedations | 2.00 | Quick Ratio | 5.75 | Shares Outstanding | 4.48M | 52W Low Chg | 1,171.00% |
| Insider Own | 4.14% | ROA | -26.11% | Shares Float | 4.30M | Beta | 1.39 |
| Inst Own | 2.67% | ROE | -48.34% | Shares Shorted/Prior | 315.10K/179.65K | Price | 2.16 |
| Gross Margin | 91.90% | Profit Margin | - | Avg. Volume | 147,167 | Target Price | - |
| Oper. Margin | -5,563.24% | Earnings Date | Nov 11 | Volume | 325,213 | Change | 0.93% |
Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
| Laidlaw & Co. | Buy | Aug 28, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Weisblum Eric | CEO and President CEO and President | Dec 14 | Buy | 1.51 | 1,100 | 1,661 | 169,224 | 12/18/23 |
| Weisblum Eric | CEO and President CEO and President | Dec 05 | Buy | 1.36 | 1,000 | 1,360 | 168,124 | 12/07/23 |
| Weisblum Eric | CEO and President CEO and President | Nov 29 | Buy | 1.55 | 2,000 | 3,100 | 167,124 | 11/30/23 |
| Weisblum Eric | CEO and President CEO and President | Nov 22 | Buy | 1.73 | 650 | 1,124 | 165,124 | 11/27/23 |
| Weisblum Eric | CEO and President CEO and President | Nov 16 | Buy | 1.44 | 2,900 | 4,176 | 160,124 | 11/20/23 |
| Weisblum Eric | CEO and President CEO and President | Dec 19 | Buy | 2.7 | 330 | 891 | 154,854 | 12/20/22 |
| Weisblum Eric | CEO, CFO and Preside.. CEO, CFO and President | Jun 17 | Buy | 0.1147 | 13,080 | 1,500 | 7,724,643 | 06/21/22 |